Terkko Navigator / Leppä, S(irpa)*

Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma

Immunogenomic Landscape of Hematological Malignancies

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma

Low Absolute Lymphocyte Counts in the Peripheral Blood Predict Inferior Survival and Improve the International Prognostic Index in Testicular Diffuse Large B-Cell Lymphoma

Immunogenomic Landscape of Hematological Malignancies

Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma

<em>STAT3</em> Mutation Is Associated with STAT3 Activation in CD30⁺ ALK^- ALCL

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma

Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Pixantrone beyond monotherapy: a review

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes

Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma

PD-L1⁺ tumor-associated macrophages and PD-1⁺ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study

Identifying differentially methylated sites in samples with varying tumor purity

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma

Clinical significance of gene defects in B-cell lymphomas

HIV infection and cancer

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma

Clinical findings in 25 patients with sinonasal or nasopharyngeal extramedullary plasmacytoma in a four-decade single-centre series

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2

Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Clinical findings of extranodal SNT lymphoid malignancies in a four-decade single-centre series

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma

Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Cutaneous T-cell Lymphoma

Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study

Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing

Activating mutations of STAT5B and STAT3 in lymphomas derived fromγδ-T or NK cells

Prognostic factors and treatment of diffuse large cell B-cell lymphoma

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study

Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma

Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma